Search

Imbalance between exogenous damaging agents and protective factors in the gastro-duodenum tract can lead to peptic ulcer disease. Herbal medicines could be an effective treatment to human gastric ulcers. This study aimed to investigate the protective effect of AGAR-HP hard capsules on cysteamine-induced gastric-duodenal ulcers in experimental rats. The animals were divided into five treatment groups: Group 1 (control) and group 2 (model) were treated with distilled water, group 3 received esomeprazole at 10 mg/kg, group 4 received AGAR-HP at 0.074 g/kg, and group 5 received AGAR-HP at 0.221 g/kg. All the rats were treated for seven consecutive days. On day 7, peptic-duodenal ulcer were induced by oral cysteamine 400 mg/kg. The number of rats with the ulcer, the number of ulcers per rat, and the ulcer index of each group were recorded. Compared to group 2, AGAR-HP at high dose reduced the mean number of ulcers and the ulcer index under macroscopic and microscopic examinations. These parameters also decreased in the group of AGAR-HP low doses compared to the cysteamine control group. AGAR-HP hard capsules showed some protective effect on cysteamine-induced gastric ulcers in experimental rats.

This study aims to assess the acute and sub-chronic oral toxicity of “Tri 02” powder in experimental animals. According to World Health Organization Guidance, acute toxicity study was conducted using Swiss mice. LD50 was determined by Litchfield-Wilcoxon method, and sub-chronic toxicity of “Tri 02” at two doses (2.4 g/kg b.w/day and 7.2 g/kg b.w/day) was assessed in Wistar rats for four uninterrupted weeks. Abnormal behavior, toxic symptoms, and death were observed for 7 consecutive days to assess the effects of acute toxicity. The general behavior of the rats was observed daily, and their body weight was recorded weekly. Hematological analysis and biochemical analysis were conducted before treatment, and at 2 and 4 weeks of treatment. Macroscopic examination and histopathological examination of several organs were conducted at the end of the treatment period. The results suggested that “Tri 02” at the highest dose used for mice (187.5 g/kg b.w) did not show acute toxicity and the LD50 was determined. In terms of the sub-chonic toxicity test, after oral administration of “Tri 02” powder, hematological parameters, hepato-renal functions and microscopic images of liver and kidney at both doses were similar to the control group. In conclusion, “Tri 02” powder did not produce the acute and subchronic oral toxicity in experimental animals.

This study was performed to investigate the effects of An Tri Khang (ATK) hard capsule on scopolamine-induced memory impairment in experimental animals. The effects on memory of oral administration ATK were evaluated on scopolamine-induced memory impairment in experimental animals. The memory improvement effects were conducted on 2 experimental models: the Morris water maze (MWM) and the Multi-T maze (MTM). In the MWM model, ATK significantly reduced the time spent and pathlength to platform, increased the percentage of time swimming in platform’s quadrant. Swiss mice performed the MTM with shorter in both the time spent and the pathlength to the goal box (p < 0.01). Both doses of ATK attenuated scopolamine-mediated impairment of memory. ATK has potential effects on memory improvement. It is suggested that further clinical trials should be undertaken to have thorough assessment on human.

Assessment of toxicities of DA.AMLODEPON HVD hard capsule on experimental animals. The acute toxicity of DA.AMLODEPON HVD was assessed on Swiss mice according to World Health Organization Guidance, and LD50 determination according to the method of Litchfield – Wilcoxon. The sub-chronic toxicity study of DA.AMLODEPON HVD at two doses (0.42 g/kg/day and 1.26g/kg/day) was conducted in rats for four consecutive weeks. After administration, general conditions and the body weight of rats were evaluated. Blood samples were collected for analyzing serum parameters before treatment (T0), second week (T1), and fourth week (T2). Histopathological analysis of livers and kidneys was observed at the end of the experiment. The results revealed that mice were taken up to a maximum dose of 39.15 g/kg with no symptoms of acute toxicity, LD50 of DA.AMLODEPON HVD has not been determined. The sub-chronic toxicity study at two doses did not change the body weight of rats, general conditions. The parameters for structures and functions of livers and kidneys and microscopic of the livers and kidneys are in a normal range during the study period.

The purpose of this research was to evaluate the acute and subchronic toxicities of An Phu Khang capsules through oral administration in experimental animals. The acute toxicity was determined by the method of Litchfield Wilcoxon in Swiss mice. The subchronic toxicity was evaluated by the recommendation of WHO in Wistar rats at these doses of 0.54 g/kg b.w/day (equal to recommended human dose) and 1.62 g/kg b.w/day (3 times as high as recommended human dose) in 4 consecutive weeks. As a result, An Phu Khang capsules at the highest dose used for mice (36.29 g/kg b.w) did not show acute toxicity in mice. In terms of the subchronic toxicity test, after oral administration of An Phu Khang capsules, hematological parameters, hepato-renal functions, and microscopic images of liver and kidney at both doses were unchanged compared with the control group. In conclusion, An Phu Khang with both doses 0.54 g/kg b.w/day and 1.62 g/kg b.w/day did not produce acute and subchronic toxicities in Swiss mice and Wistar rats.

“Kien nao dan” (KND) tablet is composed of 13 traditional medicines that may has preventive and effective treatment of cerebral ischemia. However, there are no scientific reports of its toxicological properties which guarantee of the safety its usage treatment. Therefore, the aim of this study was to investigate the sub-chronic toxicity of KND tablet on rats through oral administration. The sub-chronic toxicity was evaluated by the recommendation of WHO in Wistar rats at doses of 0.72 g/kg/day (equal to recommended human dose) and 2.16 g/kg/day (3 times as high as recommended human dose) for 8 consecutive weeks. In the evaluation of sub-chronic toxicity, there were no behavioral and physiological changes or signs of toxicity. The result of the hematological and biological parameters after administration of KND tablets showed no change. The histopathologic analysis of livers and kidneys indicated that no significant differences were observed between the exposed and unexposed rat groups. In conclusion, “Kien nao dan” tablets did not produce sub-chronic toxicity in Wistar rats.

The present study aimed to investigate the sub-chronic toxicity of “Phong thap dan” (PTD) tablets through oral administration in experimental animal. The sub-chronic toxicity was evaluated by the WHO recommendation in Wistar rats at doses of 0.72 g/kg/day (equal to recommended human dose) and 2.16 g/kg/day (3 times as high as recommended human dose). In the sub-chronic experimental group, the PTD was administered orally daily for 8 consecutive weeks. In the evaluation of sub-chronic toxicity, there were no behavioral and physiological change or sign of toxicity. The result of the hematological and biological parameters after administration of PTD tablets showed no change. The histopathology analysis of livers and kidneys indicated that no significant difference was observed between the exposed and unexposed rat groups. In conclusion, “Phong thap dan” tablets did not produce sub-chronic toxicity in Wistar rats.

Dyslipidemia is a major risk factor for cardiovascular disease. Polyherbal formulation is a traditional therapeutic strategy used to treat dyslipidemia over many years of tradition. The aim of this study was designed to evaluate the effects of Hamo NK hard capsule on endogenous dyslipidemia and exogenous dyslipidemia experimental animal model. In endogenous hyperlipidemia model, mice were previously treated by Hamo NK hard capsule, and intraperitoneally injected by poloxamer - 407 to induce hyperlipidemia. Rats were oral administration of oil - cholesterol mixture and Hamo NK for 4 consecutive weeks (exogenous dyslipidemia). Parameters of serum lipid were determined. Hamo NK ameliorated the elevation of serum total cholesterol, Non - HDL - cholesterol at the daily dose of 1.5g/kg b.w (p < 0.05). Also, there was no signicant difference in increase on high - density lipoprotein cholesterol levels and decrease triglyceride levels between the groups. Hamo NK at two doses of 0.25g/kg b.w and 0.75g/kg b.w significantly reduced serum LDL - C levels compared to the cholesterol control group. Hamo NK hard capsule affected on serum lipid modulations in dyslipidemia models.

This study evaluated the effects of Hamo NK hard capsule on athresclerosis using experimental atherosclerosis model. NewZealand White rabbits were fed a high-fat diet (HFD) containing cholesterol and peanut oil. The animals received oral administration of HFD and Hamo NK hard capsule at two doses of 0.126 and 0.378 g/kg bw/day for 8 consecutive weeks. Blood samples were collected for analyis of biochemical parameters at before treatment, week 4 and week 8. Histopathology assessments of the aortic artery and liver were carried out at the end of the experiment. Hamo NK was effective in reducing serum triglyceride level after 8 weeks of the experiment. In addition, Hamo NK at two doses of 0.126 g/kg b.w and 0.378 g/kg b.w for 8 consecutive weeks did not affect the cholesterol, LDL-C and HDL-C concentrations induced by a HFD. Hamo NK at the dose of 0.126 g/kg bw/day was not only able to decrease significant aortic surface lesions but also capable of managing atherosclerosis plaques formation in aorta; whereas theses activities were not notiaceable at the dose of 0.378 g/kg b.w.

In this study, the toxicities of “Da day An Chau” tablets (DDAC) were assessed on experimental animals. To evaluate the acute toxicity on Swiss mice according to World Health Organization Guidance and to determine LD50 refer to the method of Litchfield – Wilcoxon. The subchronic toxicity study of DDAC at two doses (0.58 g/kg/day and 1.74 g/kg/day) was conducted in rats for four consecutive weeks. Evaluation of general conditions and weight of rats during the study period. Rat’s blood was taken for hematological and biochemical evaluations. The livers and kidneys microscopes were evaluated at the end of the experiment. The result revealed that mice were taken up to a maximum dose of 25.71 g/kg with no symptoms of acute toxicity; LD50 of DDAC has not been determined. At two doses, the subchronic toxicity study did not change rats’ body weight, hematological, biochemical parameters, and microscopic of the livers and kidneys during the study period.